531000 Sigma-AldrichBrk Inhibitor, Cpd 4f - Calbiochem
A cell permeable, highly potent, and very selective inhibitor of breast tumor kinase (Brk; IC₅₀ = 3.15 nM). Displays anti-proliferative activity against multiple breast cancer cell lines.
More>> A cell permeable, highly potent, and very selective inhibitor of breast tumor kinase (Brk; IC₅₀ = 3.15 nM). Displays anti-proliferative activity against multiple breast cancer cell lines. Less<<Synonyms: PTK6 Inhibitor, Breast Tumor Kinase Inhibitor
Recommended Products
Overview
Replacement Information |
---|
Key Spec Table
Empirical Formula |
---|
C₁₇H₁₃N₃O |
Pricing & Availability
Catalogue Number | Availability | Packaging | Qty/Pack | Price | Quantity | |
---|---|---|---|---|---|---|
5.31000.0001 |
|
Glass bottle | 10 mg |
|
— |
References | |
---|---|
References | Mahmoud, K. A., et al. 2014. Bioorg. Med. Chem. Lett. 24, 1948. |
Product Information | |
---|---|
Form | Light beige powder |
Hill Formula | C₁₇H₁₃N₃O |
Chemical formula | C₁₇H₁₃N₃O |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | Brk |
Primary Target IC<sub>50</sub> | 3.15 nM |
Purity | ≥97% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Catalogue Number | GTIN |
5.31000.0001 | 04055977242485 |
Documentation
Brk Inhibitor, Cpd 4f - Calbiochem MSDS
Title |
---|
References
Reference overview |
---|
Mahmoud, K. A., et al. 2014. Bioorg. Med. Chem. Lett. 24, 1948. |
Brochure
Title |
---|
NPI Flyer- Epigenetics and Nuclear Function Feature |
New Products - Antibodies, Small Molecule, Inhibitors |
Technical Info
Title |
---|
White Paper: Further considerations of antibody validation and usage. |